Market closed

4D Molecular Therapeutics/$FDMT

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About 4D Molecular Therapeutics

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Ticker

$FDMT

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

EmeryVille, United States

Employees

147

Website

www.4dmoleculartherapeutics.com

FDMT Metrics

BasicAdvanced

$220M

-

-$2.83

2.80 -

Price and volume

Market cap

$220M

Beta

2.8

52-week high

$36.25

52-week low

$4.68

Average daily volume

944K

Financial strength

Current ratio

17.334

Quick ratio

17.033

Long term debt to equity

3.57

Total debt to equity

4.491

Management effectiveness

Return on assets (TTM)

-21.80%

Return on equity (TTM)

-32.50%

Valuation

Price to revenue (TTM)

14,251.497

Price to book

0.45

Price to tangible book (TTM)

0.45

Price to free cash flow (TTM)

-2.069

Growth

Revenue change (TTM)

-99.92%

Earnings per share change (TTM)

7.67%

3-year revenue growth (CAGR)

-90.00%

3-year earnings per share growth (CAGR)

-1.39%

What the Analysts think about FDMT

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for 4D Molecular Therapeutics stock.

FDMT Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

FDMT Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

FDMT News

AllArticlesVideos

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

GlobeNewsWire·2 months ago

Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations

Accesswire·2 months ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Accesswire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $FDMT

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for 4D Molecular Therapeutics stock?

4D Molecular Therapeutics (FDMT) has a market cap of $220M as of January 15, 2025.

What is the P/E ratio for 4D Molecular Therapeutics stock?

The price to earnings (P/E) ratio for 4D Molecular Therapeutics (FDMT) stock is 0 as of January 15, 2025.

Does 4D Molecular Therapeutics stock pay dividends?

No, 4D Molecular Therapeutics (FDMT) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next 4D Molecular Therapeutics dividend payment date?

4D Molecular Therapeutics (FDMT) stock does not pay dividends to its shareholders.

What is the beta indicator for 4D Molecular Therapeutics?

4D Molecular Therapeutics (FDMT) has a beta rating of 2.8. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.